Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

 
• By Jessica Merrill

Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.

Time out hands
Bristol's TYK2 inhibitor failed a Phase II study in ulcerative colitis • Source: Alamy

More from Immunological

More from Therapy Areas